Ceres Pharma
The computed 12-month bankruptcy probability of Ceres Pharma is 0.7% (low). The company has been active since 2015 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
| Active | 10 yrs |
| Board | 6 |
| Locations | 1 |
| Publications | 60 |
Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?
| Fiscal year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2024 | volledig | 30-07-2025 | 2025-00344192 |
| 31-12-2023 | volledig | 25-07-2024 | 2024-00290448 |
| 31-12-2022 | volledig | 29-08-2023 | 2023-00405253 |
| 31-12-2022 | consolidatie | 02-10-2023 | 2023-00471130 |
| 31-12-2021 | volledig | 11-08-2022 | 2022-20288392 |
| 31-12-2020 | volledig | 16-07-2021 | 2021-36700460 |
| 31-12-2019 | volledig | 25-08-2020 | 2020-44700170 |
| 31-12-2018 | verkort | 30-08-2019 | 2019-59700049 |
| 31-12-2017 | verkort | 28-08-2018 | 2018-52200468 |
| 31-03-2017 | verkort | 05-10-2017 | 2017-66700344 |
-
Ceres InvestLegal entityDirector· perm. rep.: Mario Leo DEBELState Gazette act 21368778 (24-11-2021)Current28-10-2021 → present
-
Current01-07-2020 → present
-
Juleste ConsultingLegal entityDirector· perm. rep.: Nathalie BaertState Gazette act 20092313 (11-08-2020)Current01-07-2020 → present
-
Current12-11-2018 → present
-
Current01-03-2016 → present
-
MD CONSULTLegal entityManaging director· perm. rep.: Mario DebelState Gazette act 15163584 (23-11-2015)Current12-11-2015 → present
Former directors (7)
-
AquitaniaLegal entityDirector· perm. rep.: Anja IMSCHOOTState Gazette act 21368778 (24-11-2021)Former— → 28-10-2021
-
Aubisque BVLegal entityDirector· perm. rep.: Freya LoncinState Gazette act 21146838 (16-12-2021)Former— → 28-10-2021
-
CRESCEMUS BVLegal entityDirector· perm. rep.: Pieter BOURGEOISState Gazette act 21368778 (24-11-2021)Former— → 28-10-2021
-
Juleste Consulting BVLegal entityDirector· perm. rep.: Nathalie BaertState Gazette act 21146838 (16-12-2021)Former— → 28-10-2021
-
MD CONSULTLegal entityDirector· perm. rep.: Mario DEBELState Gazette act 21368778 (24-11-2021)Former— → 28-10-2021
-
Michael Schenck BVBALegal entityDirector· perm. rep.: Michael SchenckState Gazette act 18171544 (30-11-2018)Former— → 12-11-2018
-
Former12-11-2015 → 01-03-2016
2 events
- 01-03-2016 Resigned· Director
- 12-11-2015 Appointed· Director
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| BV PwC BedrijfsrevisorenCurrent Statutory auditor · represented by Wouter Coppens |
— | 21-12-2020 → present |
| PricewaterhouseCoopers, BedrijfsrevisorenCurrent Company auditor · represented by Wouter Coppens |
— | 06-10-2022 → present |
| Pwc BedrijfsrevisorenCurrent Company auditor · represented by OPSOMER Peter |
— | 28-10-2021 → present |
| NACE primary | Food manufacturing(10890) |
| Legal form | Public limited company(014) |
| Incorporation | 28-10-2015 |
| Status | Active |
| Postal code | 9051 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates — not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44062B0301/00D003 | Flanders | 1.1 ha | 1 · 3,960 m² | — |
A single timeline of everything that happened to this company — publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
28-11-2025 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2025-11-20",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}28-11-2025 Articles of association amended — translation of the articles and coordination of the articles
Technical details
{
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": "BERQUIN NOTARISSEN",
"office_city": "Brussel",
"is_associated": true
},
"act_meta": {
"language": "nl",
"pub_date": "2025-11-28",
"filing_date": "2025-11-26",
"act_kind_objet": "STATUTEN (VERTALING, COORDINATIE, OVERIGE WIJZIGINGEN), KAPITAAL, AANDELEN"
},
"decision": {
"body": "notarieel_alleen",
"act_date": "2024-05-13",
"unanimous": null
},
"statute_change": {
"kinds": [
"translation",
"coordination",
"other"
],
"scope": null,
"trigger": null,
"language_after": null,
"language_before": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0641.953.324",
"name_full_after": "Ceres Pharma",
"legal_form_after": "Naamloze vennootschap",
"name_full_before": "Ceres Pharma",
"current_zetel_raw": "Kortrijksesteenweg 1091 bus B",
"legal_form_before": "Naamloze vennootschap"
},
"special_mandates": [],
"articles_modified": [],
"governance_change": null,
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Tim CARNEWAL",
"org_rep_person_name": null
},
"co_filed_documents": [
"een uitgifte van de akte",
"de geco\u00F6rdineerde tekst van statuten"
],
"shareholder_rights": null,
"voorwerp_change_summary": null,
"capital_structure_change": {
"operations": [
"capital_increase_kind"
],
"split_ratio": null,
"shares_after": 167917449,
"shares_before": null,
"capital_after_eur": 50375234.71,
"capital_before_eur": null,
"share_classes_after": []
},
"coordinated_text_lineage": null
}28-11-2025 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma"
},
"legal_form_change": {
"new": "",
"old": "Naamloze vennootschap",
"changed": false
}
}28-11-2025 Capital increase of €50,375,234.71 to €50,375,234.71
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 50375234.71,
"currency": "EUR",
"after_eur": 50375234.71,
"delta_eur": 50375234.71,
"before_eur": null,
"amount_type": "kapitaal_effectief",
"effective_date": "2024-05-13",
"evidence_quote": "De vergadering stelt vast en verzoekt ons, notaris, akte te nemen van het feit dat de voormelde kapitaalverhoging daadwerkelijk verwezenlijkt werd en dat het kapitaal aldus daadwerkelijk gebracht werd op EUR 50.375.234,71",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}28-11-2025 Capital increase
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 167917449,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "inschrijvingsrechten_uitgifte",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": "BERQUIN NOTARISSEN",
"office_city": "Brussel",
"is_associated": true
},
"act_meta": {
"language": "nl",
"pub_date": "2025-11-28",
"filing_date": "2025-11-26",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "algemene_vergadering",
"act_date": "2024-05-13",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma",
"legal_form": "Naamloze vennootschap",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": null,
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"een uitgifte van de akte",
"de geco\u00F6rdineerde tekst van statuten"
],
"shareholders_after": [],
"share_classes_after": []
}28-11-2025 Capital increase to €50,375,234.71
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 50375234.71,
"delta_eur": null,
"before_eur": null,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma"
}
}19-08-2025 1 director appointed, 1 resigning
- Wouter Coppens — Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Wouter Coppens",
"address": null,
"birth_date": null,
"profession": "bedrijfsrevisor",
"birth_place": null
},
"reason": null,
"subkind": "renewal",
"via_org": {
"kbo": null,
"name": "PwC Bedrijfsrevisoren BV",
"address": "Culliganlaan 5, 1831 Diegem",
"country": "BE",
"legal_form": "BV"
},
"statutory": "statutair",
"compensated": null,
"effective_date": "2023-07-01",
"evidence_quote": "De Firma PwC Bedrijfsrevisoren zal vanaf 1 juli 2023 vertegenwoordigd worden door de heer Wouter Coppens, in de uitoefening van zijn mandaat van Commissaris, ter vervanging van de heer Peter Opsomer.",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": 3
},
"rep_rotation_new_rep": "Wouter Coppens",
"rep_rotation_old_rep": "Peter Opsomer",
"effective_date_qualifier": null
},
{
"kind": "decharge_granted",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Wouter Coppens",
"address": null,
"birth_date": null,
"profession": "bedrijfsrevisor",
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": {
"kbo": null,
"name": "PwC Bedrijfsrevisoren BV",
"address": "Culliganlaan 5, 1831 Diegem",
"country": "BE",
"legal_form": "BV"
},
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "Deze vennootschap wijst overeenkomstig artikel 3:60 WVV Wouter Coppens BV, aan, voor de uitoefening van het mandaat, met als vaste vertegenwoordiger Wouter Coppens, bedrijfsrevisor.",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "decharge_granted",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Peter Opsomer",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": null,
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "mandate_termination_de_plein_droit",
"role": "commissaris",
"person": null,
"reason": null,
"subkind": null,
"via_org": null,
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "Het mandaat vervalt na de algemene vergadering die de jaarrekening per 31 december 2025 dient goed te keuren",
"decharge_status": null,
"mandate_duration": {
"kind": "until_agm_year",
"value": 2025
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": null,
"filing_date": "2025-08-07",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "algemene_vergadering",
"date": "2023-06-23",
"unanimous": null
}
],
"is_correction": false,
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma NV",
"legal_form": "NV"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Mario Debel",
"org_rep_person_name": null,
"person_role_at_subject": "Aandeelhouder/Bestuurder"
},
"co_filed_documents": [],
"corrected_publication_numac": null
}19-08-2025 Wouter Coppens appointed as statutory auditor
- Wouter Coppens — Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Wouter Coppens",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "PwC Bedrijfsrevisoren BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2023-07-01",
"evidence_quote": "De algemene vergadering benoemt PwC Bedrijfsrevisoren BV, met maatschappelijke zetel te 1831 Diegem, Culliganlaan 5, als commissaris voor een termijn van drie jaar."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}19-08-2025 1 director appointed, 1 resigning
- Wouter Coppens — Commissaris
- Peter Opsomer — Commissaris
Technical details
{
"events": [
{
"kind": "director_in",
"role": "Commissaris",
"person": {
"rrn": null,
"name": "Wouter Coppens",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Commissaris",
"person": {
"rrn": null,
"name": "Peter Opsomer",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma NV"
}
}03-09-2024 Wouter Coppens reappointed as statutory auditor
- Wouter Coppens — Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_renew",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Wouter Coppens",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0641953324",
"name": "PwC Bedrijfsrevisoren BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2023-07-01",
"evidence_quote": "De firma PwC Bedrijfsrevisoren BV zal vanaf 1 juli 2023 vertegenwoordigd worden door de heer Wouter Coppens, in de uitoefening van zijn mandaat van commissaris, ter vervanging van de heer Peter Opsomer."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}03-09-2024 1 director appointed, 1 resigning
- Wouter Coppens — Commissaris
- Peter Opsomer — Commissaris
Technical details
{
"events": [
{
"kind": "director_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Wouter Coppens",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Peter Opsomer",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma"
}
}03-09-2024 1 director appointed, 1 resigning
- Wouter Coppens — Commissaris
- Peter Opsomer — Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Wouter Coppens",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "successor_conditional",
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": "2023-07-01",
"evidence_quote": "De firma PwC Bedrijfsrevisoren BV zal vanaf 1 juli 2023 vertegenwoordigd worden door de heer Wouter Coppens, in de uitoefening van zijn mandaat van commissaris, ter vervanging van de heer Peter Opsomer.",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": "Wouter Coppens",
"rep_rotation_old_rep": "Peter Opsomer",
"effective_date_qualifier": null
},
{
"kind": "commissaris_out",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Peter Opsomer",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": "2023-07-01",
"evidence_quote": "De firma PwC Bedrijfsrevisoren BV zal vanaf 1 juli 2023 vertegenwoordigd worden door de heer Wouter Coppens, in de uitoefening van zijn mandaat van commissaris, ter vervanging van de heer Peter Opsomer.",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "decharge_granted",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Wouter Coppens",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "decharge_granted",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Peter Opsomer",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "decharge_granted",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Mario Debel",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": {
"kbo": null,
"name": "Ceres Invest BV",
"address": null,
"country": null,
"legal_form": "BV"
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Gent",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2024-09-03",
"filing_date": "2024-08-23",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "algemene_vergadering",
"date": "2023-06-23",
"unanimous": null
}
],
"is_correction": false,
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma",
"legal_form": "NV"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Mario Debel",
"org_rep_person_name": null,
"person_role_at_subject": "Aandeelhouder/Bestuurder"
},
"co_filed_documents": [],
"corrected_publication_numac": null
}27-05-2024 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma"
},
"legal_form_change": {
"new": "Naamloze vennootschap",
"old": "Naamloze vennootschap",
"changed": false
}
}27-05-2024 Capital increase of €4,608,796.87 to €50,375,234.71
- €45.766.437,84 → €50.375.234,71
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 50375234.71,
"delta_eur": 4608796.87,
"before_eur": 45766437.84,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 15362656,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 0.3
},
"decrease_purpose": null,
"contribution_type": "inschrijvingsrechten_uitgifte",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": "BERQUIN NOTARISSEN",
"office_city": "Brussel",
"is_associated": true
},
"act_meta": {
"language": "nl",
"pub_date": "2024-05-27",
"filing_date": "2024-05-23",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2024-05-13",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": {
"waived": false,
"firm_kbo": null,
"firm_name": "PwC Bedrijfsrevisoren BV",
"ibr_number": null,
"mission_type": "apport_nature",
"individual_name": "Wouter Coppens"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma",
"legal_form": "Naamloze vennootschap",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"uitgifte van het proces-verbaal",
"volmacht",
"de geco\u00F6rdineerde tekst van statuten",
"het verslag van het bestuursorgaan",
"het verslag van de commissaris"
],
"shareholders_after": [],
"share_classes_after": []
}27-05-2024 Capital increase of €4,608,796.87 to €50,375,234.71
- €45.766.437,84 → €50.375.234,71
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 4608796.87,
"currency": "EUR",
"after_eur": 50375234.71,
"delta_eur": 4608796.87,
"before_eur": 45766437.84,
"amount_type": "kapitaal_effectief",
"effective_date": "2024-05-13",
"evidence_quote": "De vergadering beslist het kapitaal van de Vennootschap te verhogen ten belope van EUR 4.608.796,87, om het van EUR 45.766.437,84 te brengen op EUR 50.375.234,71, door uitgifte van 15.362.656 aandelen ... De vergadering beslist dat de kapitaalverhoging zal worden verwezenlijkt door de inbreng door de enige aandeelhouder van een zekere, vaststaande en opeisbare schuldvordering",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}27-05-2024 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2024-05-13",
"legal_form_change": false
},
"bedrijfsrevisor": {
"quote": "de conclusies van het verslag van de commissaris de dato 10 mei 2024, opgesteld door de besloten vennootschap \u201CPricewaterhouseCoopers Bedrijfsrevisoren\u201D, te Gent, vertegenwoordigd door de heer Wouter Coppens, in toepassing van de artikelen 7:179, \u00A71, tweede lid en 7:197, \u00A71, tweede lid van het Wetboek van vennootschappen en verenigingen",
"firm_kbo": null,
"firm_name": "PricewaterhouseCoopers Bedrijfsrevisoren",
"ibr_number": null,
"individual_name": "Wouter Coppens"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}27-05-2024 Capital increase of €4,608,796.87 to €50,375,234.71
- €45.766.437,84 → €50.375.234,71
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 50375234.71,
"delta_eur": 4608796.869999997,
"before_eur": 45766437.84,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma"
}
}31-01-2024 Capital increase of €9,999,999.90 to €45,766,437.84
- €35.766.437,94 → €45.766.437,84
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 9999999.9,
"currency": "EUR",
"after_eur": 45766437.84,
"delta_eur": 9999999.9,
"before_eur": 35766437.94,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-12-21",
"evidence_quote": "De vergadering beslist het kapitaal van de Vennootschap te verhogen ten belope van 9.999.999,90 EUR, om het van 35.766.437,94 EUR te brengen op 45.766.437,84 EUR, door inbreng in geld",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}31-01-2024 Capital increase of €9,999,999.90 to €45,766,437.84
- €35.766.437,94 → €45.766.437,84
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 45766437.84,
"delta_eur": 9999999.900000006,
"before_eur": 35766437.94,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma"
}
}31-01-2024 Capital increase of €9,999,999.90 to €45,766,437.84
- €35.766.437,94 → €45.766.437,84
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 45766437.84,
"delta_eur": 9999999.9,
"before_eur": 35766437.94,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 33333333,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 0.3
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 9999999.9,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": "BERQUIN NOTARISSEN",
"office_city": "Brussel",
"is_associated": true
},
"act_meta": {
"language": "nl",
"pub_date": "2024-01-31",
"filing_date": "2024-01-29",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2023-12-21",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma",
"legal_form": "Naamloze vennootschap",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"uitgifte van het proces-verbaal",
"een volmacht",
"de geco\u00F6rdineerde tekst van de statuten"
],
"shareholders_after": [],
"share_classes_after": []
}17-05-2023 Capital increase of €3,499,997.94 to €35,766,437.94
- €32.266.440 → €35.766.437,94
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 35766437.94,
"delta_eur": 3499997.9399999976,
"before_eur": 32266440.0,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma"
}
}17-05-2023 Capital increase of €3,499,997.94 to €35,766,437.94
- €32.266.440 → €35.766.437,94
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 35766437.94,
"delta_eur": 3499997.94,
"before_eur": 32266440.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 11666660,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 0.3
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 3499997.94,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": "BERQUIN NOTARISSEN",
"office_city": "Brussel",
"is_associated": true
},
"act_meta": {
"language": "nl",
"pub_date": "2023-05-17",
"filing_date": "2023-05-15",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2023-05-05",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma",
"legal_form": "Naamloze vennootschap",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"een uitgifte van het proces-verbaal",
"\u00E9\u00E9n volmacht",
"de geco\u00F6rdineerde tekst van de statuten"
],
"shareholders_after": [],
"share_classes_after": []
}17-05-2023 Capital increase of €3,499,997.94 to €35,766,437.94
- €32.266.440 → €35.766.437,94
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 3499997.94,
"currency": "EUR",
"after_eur": 35766437.94,
"delta_eur": 3499997.94,
"before_eur": 32266440.0,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-05-05",
"evidence_quote": "De vergadering beslist het kapitaal van de Vennootschap te verhogen ten belope van 3.499.997,94 EUR, om het van 32.266.440,00 EUR te brengen op 35.766.437,94 EUR, door inbreng in geld",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}18-10-2022 Capital increase of €10,329,960 to €32,566,400
- €22.236.440 → €32.566.400
- 4 kapitaalbewegingen in deze akte
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 10356000.0,
"delta_eur": 4356000.0,
"before_eur": 6000000.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 14520000,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 0.3
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 4356000.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": 14149440.0,
"delta_eur": 3793440.0,
"before_eur": 10356000.0,
"subscribers": [
{
"kbo": null,
"rrn": null,
"kind": "org",
"name": "eenige aandeelhouder",
"share_class": null,
"liberation_pct": null,
"contribution_kind": "schuldvordering",
"n_shares_subscribed": null,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 12644800,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "natura",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": 22236440.0,
"delta_eur": 8087000.0,
"before_eur": 14149440.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": null,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "inschrijvingsrechten_uitgifte",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": 32566400.0,
"delta_eur": 10329960.0,
"before_eur": 22236440.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": null,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "kapitalisering_reserves",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
}
],
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": "BERQUIN NOTARISSEN",
"office_city": "Brussel",
"is_associated": true
},
"act_meta": {
"language": "nl",
"pub_date": "2022-10-18",
"filing_date": "2022-10-14",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2022-10-28",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": {
"waived": false,
"firm_kbo": null,
"firm_name": "PwC Bedrijfsrevisoren BV",
"ibr_number": null,
"mission_type": "quasi_apport",
"individual_name": "Peter Opsomer"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma",
"legal_form": "Naamloze vennootschap",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"een uitgifte van het proces-verbaal",
"\u00E9\u00E9n volmacht",
"een verslag van het bestuursorgaan",
"een verslag van de commissaris",
"de geco\u00F6rdineerde tekst van statuten"
],
"shareholders_after": [],
"share_classes_after": []
}18-10-2022 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma"
},
"legal_form_change": {
"new": "Naamloze vennootschap",
"old": "Naamloze vennootschap",
"changed": false
}
}18-10-2022 Capital increase of €8,149,440 to €32,266,440
- €24.117.000 → €32.266.440
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 32266440,
"delta_eur": 8149440,
"before_eur": 24117000,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma"
}
}18-10-2022 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2022-10-06",
"legal_form_change": false
},
"bedrijfsrevisor": {
"quote": "Conclusies van het verslag van de commissaris de dato 5 oktober 2022, opgesteld door de besloten vennootschap \u201CPricewaterhouseCoopers Bedrijfsrevisoren\u201D, te Culliganlaan 5, 1831 Machelen, vertegenwoordigd door Peter Opsomer, in toepassing van de artikelen 7:179, \u00A71, tweede lid en 7:197, \u00A71, tweede lid van het Wetboek van vennootschappen en verenigingen, luiden letterlijk als volgt: ... waarvoor wij werden aangesteld bij opdrachtbrief van 4 oktober 2022.",
"firm_kbo": null,
"firm_name": "PricewaterhouseCoopers Bedrijfsrevisoren",
"ibr_number": null,
"individual_name": "Peter Opsomer"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}18-10-2022 Capital increase of €4,356,000 to €28,473,000
- €24.117.000 → €28.473.000
- 2 kapitaalbewegingen in deze akte
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 4356000,
"currency": "EUR",
"after_eur": 28473000,
"delta_eur": 4356000,
"before_eur": 24117000,
"amount_type": "kapitaal_effectief",
"effective_date": "2022-10-06",
"evidence_quote": "De vergadering beslist het kapitaal van de Vennootschap te verhogen ten belope van 4.356.000 EUR, om het van 24.117.000 EUR te brengen op 28.473.000 EUR, door inbreng in geld",
"contribution_type": "cash"
},
{
"kind": "capital_increase",
"amount": 3793440,
"currency": "EUR",
"after_eur": 32266440,
"delta_eur": 3793440,
"before_eur": 28473000,
"amount_type": "kapitaal_effectief",
"effective_date": "2022-10-06",
"evidence_quote": "De vergadering beslist het kapitaal van de Vennootschap te verhogen ten belope van 3.793.440 EUR om het van 28.473.000 EUR te brengen op 32.266.440 EUR, door inbreng in natura",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}15-02-2022 Registered office moved from Merelbeke to Sint-Denijs-Westrem
- Lembergsesteenweg 25, bus A, 9820 Merelbeke → Kortrijksesteenweg 1091 bus B, 9051 Sint-Denijs-Westrem
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "Kortrijksesteenweg 1091 bus B, 9051 Sint-Denijs-Westrem",
"city": "Sint-Denijs-Westrem",
"region": "vlaams_gewest",
"street": "Kortrijksesteenweg",
"country": "BE",
"postcode": "9051",
"box_number": "B",
"street_number": "1091",
"locality_suffix": null
},
"old_address": {
"raw": "Lembergsesteenweg 25, bus A, 9820 Merelbeke",
"city": "Merelbeke",
"region": "vlaams_gewest",
"street": "Lembergsesteenweg",
"country": "BE",
"postcode": "9820",
"box_number": "A",
"street_number": "25",
"locality_suffix": null
},
"effective_date": "2022-01-25",
"evidence_quote": "De bestuurder besluit om de zetel te verplaatsen van Lembergsesteenweg 25a, 9820 Merelbeke, naar Kortrijksesteenweg 1091 bus B, 9051 Sint-Denijs-Westrem, met ingang van heden.",
"region_changed": false,
"is_statute_change": false,
"nationality_change": false,
"old_address_source": "act_body",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "immediate",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": "Notaris niet vermeld",
"firm_city": null,
"firm_name": null,
"office_city": "Gent",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": null,
"filing_date": "2022-01-25",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "enige_bestuurder",
"date": "2022-01-25",
"unanimous": true
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Ceres Pharma",
"legal_form": "NV"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Julie De Craecker",
"org_rep_person_name": null,
"person_role_at_subject": "vertegenwoordiging bij administratieve formaliteiten"
},
"co_filed_documents": [
"Bijzondere volmacht voor Julie De Craecker",
"Formulier voor publicatie in het Belgisch Staatsblad"
]
}15-02-2022 Registered office moved from Merelbeke to Sint-Denijs-Westrem
- Lembergsesteenweg 25, 9820 Merelbeke → Kortrijksesteenweg 1091, 9051 Sint-Denijs-Westrem
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Sint-Denijs-Westrem",
"region": null,
"street": "Kortrijksesteenweg",
"country": "BE",
"postcode": "9051",
"box_number": "B",
"street_number": "1091"
},
"old_address": {
"city": "Merelbeke",
"region": null,
"street": "Lembergsesteenweg",
"country": "BE",
"postcode": "9820",
"box_number": "A",
"street_number": "25"
},
"effective_date": "2022-01-25",
"evidence_quote": "De bestuurder besluit om de zetel te verplaatsen van Lembergsesteenweg 25a, 9820 Merelbeke, naar Kortrijksesteenweg 1091 bus B, 9051 Sint-Denijs-Westrem, met ingang van heden."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | Ceres Pharma |